DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,755 filers reported holding DANAHER CORPORATION in Q1 2021. The put-call ratio across all filers is 0.86 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,460,322 | -5.8% | 5,886 | -8.9% | 0.14% | -2.9% |
| Q2 2023 | $1,550,406 | -6.1% | 6,460 | -1.4% | 0.14% | -13.1% |
| Q1 2023 | $1,651,372 | -3.2% | 6,552 | +1.9% | 0.16% | -9.6% |
| Q4 2022 | $1,706,391 | +2.0% | 6,429 | -0.8% | 0.18% | +13.5% |
| Q3 2022 | $1,673,000 | -11.2% | 6,478 | +0.2% | 0.16% | -4.3% |
| Q2 2022 | $1,885,000 | +2.6% | 6,468 | +3.3% | 0.16% | +4.5% |
| Q1 2022 | $1,837,000 | -6.6% | 6,263 | +4.8% | 0.16% | -9.8% |
| Q4 2021 | $1,966,000 | +11.0% | 5,975 | +2.7% | 0.17% | -1.1% |
| Q3 2021 | $1,771,000 | +15.7% | 5,817 | +2.0% | 0.18% | +15.9% |
| Q2 2021 | $1,531,000 | +18.6% | 5,704 | -0.5% | 0.15% | +18.0% |
| Q1 2021 | $1,291,000 | -2.3% | 5,735 | -3.6% | 0.13% | -5.9% |
| Q4 2020 | $1,321,000 | +3.5% | 5,948 | +0.4% | 0.14% | -3.5% |
| Q3 2020 | $1,276,000 | +20.3% | 5,924 | -1.3% | 0.14% | +11.0% |
| Q2 2020 | $1,061,000 | +25.4% | 6,001 | -1.8% | 0.13% | +56.8% |
| Q1 2020 | $846,000 | -4.4% | 6,110 | +6.0% | 0.08% | -31.4% |
| Q4 2019 | $885,000 | +6.2% | 5,765 | -0.1% | 0.12% | +9.3% |
| Q3 2019 | $833,000 | -24.1% | 5,769 | -24.9% | 0.11% | -22.9% |
| Q2 2019 | $1,098,000 | +8.2% | 7,683 | -0.1% | 0.14% | +17.6% |
| Q1 2019 | $1,015,000 | +26.2% | 7,691 | -1.4% | 0.12% | +14.4% |
| Q4 2018 | $804,000 | -13.1% | 7,799 | -8.4% | 0.10% | -2.8% |
| Q3 2018 | $925,000 | +23.2% | 8,513 | +11.8% | 0.11% | +13.8% |
| Q2 2018 | $751,000 | +2.7% | 7,615 | +2.1% | 0.09% | -2.1% |
| Q1 2018 | $731,000 | -3.9% | 7,461 | -9.0% | 0.10% | -5.9% |
| Q4 2017 | $761,000 | +60.5% | 8,203 | +48.4% | 0.10% | +112.5% |
| Q3 2017 | $474,000 | +5.1% | 5,527 | +3.4% | 0.05% | -2.0% |
| Q2 2017 | $451,000 | -16.9% | 5,344 | -15.8% | 0.05% | -21.0% |
| Q1 2017 | $543,000 | +19.9% | 6,348 | +9.0% | 0.06% | +1.6% |
| Q4 2016 | $453,000 | +0.9% | 5,822 | +1.7% | 0.06% | +19.6% |
| Q3 2016 | $449,000 | -21.4% | 5,723 | +1.3% | 0.05% | -21.5% |
| Q2 2016 | $571,000 | +9.6% | 5,651 | +2.8% | 0.06% | -44.0% |
| Q1 2016 | $521,000 | -8.0% | 5,496 | -9.8% | 0.12% | -18.9% |
| Q4 2015 | $566,000 | +35.4% | 6,092 | +24.1% | 0.14% | +26.5% |
| Q3 2015 | $418,000 | +5.6% | 4,910 | +6.0% | 0.11% | +8.7% |
| Q2 2015 | $396,000 | -12.2% | 4,632 | -12.8% | 0.10% | -21.8% |
| Q1 2015 | $451,000 | +6.9% | 5,312 | +7.8% | 0.13% | -15.8% |
| Q4 2014 | $422,000 | +19.9% | 4,929 | +6.5% | 0.16% | +9.0% |
| Q3 2014 | $352,000 | +34.4% | 4,627 | +38.9% | 0.14% | +21.8% |
| Q2 2014 | $262,000 | +23.6% | 3,330 | +17.7% | 0.12% | -8.5% |
| Q1 2014 | $212,000 | – | 2,829 | – | 0.13% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |